November 22, 2022
2 min watch
Tantravahi reports consulting and serving on advisory boards for AbbVie, Karyopharm Therapeutics and Novartis; and providing clinical research support for Karyopharm Therapeutics.
In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), discussed a case study, presented at the 14th International Congress on Myeloproliferative Neoplasms, of dizygotic twins.
According to Tantravahi, hematologist with University of Utah Health and Huntsman Cancer Institute, the first twin was initially diagnosed with JAK2-positive myeloproliferative neoplasm polycythemia vera that eventually progressed to myelofibrosis while the second twin subsequently presented with JAK2-positive myeloproliferative neoplasm.
He noted that a group from the U.K. has shown that the JAK2 mutation can be acquired in utero as a somatic event. The mutation can also be picked up years before a diagnosis.
“Having a real-life case to support that data from the U.K. group is encouraging,” Tantravahi said.
- Parsegov BH. Dizygotic twins with JAK2V617F mutation positive myeloproliferative neoplasms arising from a potential chimerism occurring through placental anastomoses. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.